MarketCap
Facebook
X
Telegram
BeiGene, Ltd. Market Cap | BGNE
As of October 25, 2026 BeiGene, Ltd. has a market cap of $ 251 B
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap BeiGene, Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 253 B | 217 B | 291 B | 293 B | 347 B | 9.22 B | 7.01 B | 5.64 B | 1.35 B | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 347 B | 1.35 B | 158 B |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Corcept Therapeutics Incorporated
CORT
|
3.75 B | $ 85.86 | -20.13 % | $ 8.92 B |  USA |
 |
CorMedix
CRMD
|
456 K | $ 7.85 | -3.09 % | $ 565 K | USA |
 |
CRISPR Therapeutics AG
CRSP
|
4.39 B | $ 49.39 | -1.2 % | $ 4.44 B |  Schweiz |
 |
Greenwich LifeSciences
GLSI
|
386 M | $ 16.03 | 3.55 % | $ 217 M | USA |
 |
Champions Oncology
CSBR
|
83.8 M | $ 4.72 | -0.84 % | $ 65.3 M | USA |
 |
Heat Biologics, Inc.
HTBX
|
32.8 M | - | -5.76 % | $ 99.8 M | USA |
 |
Cue Biopharma
CUE
|
29.4 M | $ 18.66 | -1.22 % | $ 1.77 B | USA |
 |
Kindred Biosciences, Inc.
KIN
|
196 M | - | 0.11 % | $ 419 M | USA |
 |
DBV Technologies S.A.
DBVT
|
2.82 B | $ 9.75 | 0.72 % | $ 1.36 B |  France |
 |
Alterity Therapeutics Limited
ATHE
|
29.4 B | $ 2.09 | -2.79 % | $ 13.4 B |  Australia |
 |
Shineco, Inc.
TYHT
|
13.2 M | - | -3.90 % | $ 97.2 M |  China |
 |
Actinium Pharmaceuticals
ATNM
|
30.9 M | $ 1.52 | -2.56 % | $ 47.4 M | USA |
 |
Millendo Therapeutics, Inc.
MLND
|
2.5 M | - | -5.36 % | $ 20.2 M | USA |
 |
DiaMedica Therapeutics
DMAC
|
312 M | $ 8.72 | 1.04 % | $ 410 M | USA |
 |
Aytu BioScience
AYTU
|
27.5 M | $ 1.9 | -4.04 % | $ 23.4 M | USA |
 |
Dyadic International
DYAI
|
31.5 M | $ 0.4 | -0.75 % | $ 14.5 M | USA |
 |
Intec Pharma Ltd
NTEC
|
16.1 M | - | -12.45 % | $ 17.7 M |  Israel |
 |
Edesa Biotech
EDSA
|
11.3 M | $ 2.77 | 0.36 % | $ 15.7 M | USA |
 |
Progenity, Inc.
PROG
|
339 M | - | -3.47 % | $ 164 M | USA |
 |
Lantern Pharma
LTRN
|
13.5 M | $ 0.64 | -0.83 % | $ 6.97 M | USA |
 |
Strongbridge Biopharma plc
SBBP
|
151 M | - | 1.52 % | $ 136 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
169 M | $ 10.08 | -2.33 % | $ 288 M | USA |
 |
Seneca Biopharma, Inc.
SNCA
|
538 K | - | -1.19 % | $ 28.7 M | USA |
 |
Cardiff Oncology
CRDF
|
116 M | $ 0.91 | -2.23 % | $ 60.8 M | USA |
 |
Inhibrx
INBX
|
1.75 B | $ 93.38 | -3.83 % | $ 4.4 B | USA |
 |
Eton Pharmaceuticals
ETON
|
559 M | $ 50.0 | -0.04 % | $ 1.35 B | USA |
 |
ImmuCell Corporation
ICCC
|
58 M | $ 10.25 | -1.82 % | $ 92.5 M | USA |
 |
Fulcrum Therapeutics
FULC
|
539 M | $ 3.68 | -0.14 % | $ 233 M | USA |
 |
Kamada Ltd.
KMDA
|
490 M | $ 7.77 | 0.52 % | $ 448 M | Israel |
 |
IDEAYA Biosciences
IDYA
|
2.73 B | $ 34.71 | -3.9 % | $ 3.07 B | USA |
 |
InflaRx N.V.
IFRX
|
63.3 M | $ 1.56 | 1.96 % | $ 105 M |  Germany |
 |
Immutep Limited
IMMP
|
2.97 B | $ 3.2 | 1.91 % | $ 4.66 B | Australia |
 |
Mustang Bio
MBIO
|
4.17 M | $ 0.37 | 0.22 % | $ 1.82 M | USA |
 |
Kala Pharmaceuticals
KALA
|
1.63 M | $ 0.19 | 2.48 % | $ 1.55 M | USA |
 |
Mereo BioPharma Group plc
MREO
|
2.03 B | $ 0.28 | -1.98 % | $ 223 M |  Britain |
 |
Kiniksa Pharmaceuticals, Ltd.
KNSA
|
3.28 B | $ 76.73 | -5.03 % | $ 5.69 B | USA |
 |
Karyopharm Therapeutics
KPTI
|
45.1 K | $ 0.52 | -5.24 % | $ 5.69 K | USA |
 |
Seres Therapeutics
MCRB
|
62 M | $ 2.09 | -1.88 % | $ 18.5 M | USA |
 |
MediWound Ltd.
MDWD
|
131 M | $ 12.0 | -1.48 % | $ 327 M | Israel |
 |
Precigen
PGEN
|
970 M | $ 6.19 | -3.13 % | $ 1.94 B | USA |
 |
PolyPid Ltd.
PYPD
|
67.7 M | $ 5.25 | 2.34 % | $ 85.8 M | Israel |
 |
Rocket Pharmaceuticals
RCKT
|
308 M | $ 2.29 | -0.87 % | $ 254 M | USA |
 |
Avidity Biosciences
RNA
|
10 B | $ 8.2 | 0.49 % | $ 1.13 B | USA |
 |
Summit Therapeutics
SMMT
|
12 B | $ 15.47 | -0.51 % | $ 11.6 B | Britain |
 |
Celsion Corporation
CLSN
|
2.01 M | - | -6.63 % | $ 13.9 M | USA |
 |
I-Mab
IMAB
|
127 M | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
168 B | - | 2.54 % | $ 160 B | France |
 |
Biophytis SA
BPTS
|
179 M | - | -13.47 % | $ 169 M | France |